ABBV stock: Phase 3 lymphoma trial reduces risk of disease progression by 51%

TLDR

AbbVie's Phase 3 clinical trial has reached key goals for lymphoma treatment, and Epcoritamab is expected to expand its strategy in frontline lymphoma treatment. AbbVie and Genmab are preparing for regulatory discussions.

AbbVie Phase 3 lymphoma trial reduces the risk of progression or death in patients with diffuse large B-cell lymphoma (DLBCL) by 51%

Epcoritamab combined with the R-CHOP regimen has achieved a major Phase 3 trial victory in the treatment of first-line lymphoma. AbbVie has released new lymphoma data, and the EPCORE DLBCL-2 study has reached its primary endpoint. These Phase 3 results strengthen AbbVie's bispecific antibody strategy in the treatment of first-line DLBCL. AbbVie and Genmab plan to have regulatory communication following positive lymphoma trial results.

AbbVie announced positive Phase 3 lymphoma trial results after its share price rose 1.12% to $265.76. The EPCORE DLBCL-2 study showed a 51% reduction in the risk of disease progression or death. The finding may strengthen AbbVie's position in the front-line treatment of diffuse large B-cell lymphoma.

AbbVie Phase 3 trial achieves key lymphoma goals

AbbVie and Genmab tested the use of epcoritamab in combination with standard R-CHOP therapy in patients with newly diagnosed DLBCL. The trial included patients with International Prognostic Index (IPI) scores between 2 and 5. The researchers compared the combination treatment regimen directly to R-CHOP treatment alone.

The study achieved the goal of progression-free survival with statistically significant and clinically meaningful results. Epcoritamab combined with R-CHOP reduced the risk of progression or death by 51% compared to standard therapy. The hazard ratio reported in the test was 0.49, and the P value was less than 0.0001.

The company also reported an overall controllable safety profile for combination therapy. The researchers found safety results consistent with previous results from epcoritamab and R-CHOP alone. As a result, AbbVie has gained stronger phase 3 evidence to support the use of epcoritamab for early lymphoma treatment.

Epcoritamab is expected to expand AbbVie's frontline lymphoma strategy

DLBCL is an aggressive form of non-Hodgkin's lymphoma that often requires immediate treatment. R-CHOP has been a core first-line treatment for many patients for years. However, some patients still experience disease progression or recurrence after initial treatment.

Epcoritamab uses a bispecific antibody method to allow T cells to act against cancer cells. AbbVie and Genmab designed the treatment regimen to target CD3 on T cells and CD20 on B cells. This method aims to increase immune activity against malignant B cells.

If regulators approve the combination therapy, the latest results may extend the use of epcoritamab to more advanced treatment stages. AbbVie has identified bispecific antibodies as an important part of its hematology development strategy. These Phase 3 results provide the company with additional clinical data to support the strategy.

AbbVie and Genmab prepare for regulatory discussions

AbbVie and Genmab plan to publish detailed EPCORE DLBCL-2 results at a future medical meeting. The companies will also discuss the findings with regulators in key global markets. These dialogues will help determine the next development and declaration steps.

This combination therapy is still in the research stage and has not yet received regulatory approval for patients with newly diagnosed DLBCL. Regulatory agencies will evaluate complete efficacy and safety data before making any authorization decisions. As a result, AbbVie must complete further regulatory work before such uses can be commercialized.

Epcoritamab is part of a broader collaboration between AbbVie and Genmab on the treatment of hematological cancer. The two companies have continued to study the drug in multiple lymphoma scenarios and treatment phases. The latest Phase 3 results add frontline DLBCL to this growing clinical development program.